Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity

J.S. Lind, P.E. Postmus*, D.A. Heideman, E.B. Thunnissen, O. Bekers, E.F. Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity'. Together they form a unique fingerprint.

Keyphrases

INIS

Pharmacology, Toxicology and Pharmaceutical Science